HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Slomovitz, B. M. Articles by Lu, K. H. Search for Related Content PubMed PubMed Citation Articles by Slomovitz, B. M. Articles by Lu, K. H. Related Collections Breast Disease Gynecologic oncology

Does Tamoxifen Use Affect Prognosis in Breast Cancer Patients Who Develop Endometrial Cancer?

From the Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

Address reprint requests to: Karen H. Lu, MD, Department of Gynecologic Oncology, Unit 440, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009; e-mail: khlu{at}mdanderson.org.

OBJECTIVE: The use of tamoxifen to prevent breast cancer and decrease recurrence is not controversial. However, the effect that tamoxifen may have in women with a history of breast cancer in whom endometrial cancer develops is unclear. The purpose of this study was to estimate whether a history of tamoxifen use is a prognostic factor for such patients.

METHODS: Between 1990 and 2002, patients seen at The University of Texas M. D. Anderson Cancer Center with a history of breast cancer who developed endometrial cancer were identified. Medical records were reviewed to identify clinical, pathologic, and outcome information.

RESULTS: Eighty-nine patients with a history of breast cancer in whom endometrial carcinoma developed were identified. Fifty-two percent (46/89) had a history of tamoxifen use (median duration 48 months; range 2–120 months). There were no significant differences in the clinical or pathologic features between tamoxifen users and nonusers. A history of tamoxifen use was associated with a shorter interval from breast cancer to endometrial cancer diagnosis (77.2 versus 121.3 months for nonusers; P = .01). There was no significant difference in overall survival between tamoxifen users and nonusers (39.2 months versus 48.3 months, P = .27), and there was no difference in endometrial cancer-specific survival duration between tamoxifen users and nonusers (55.7 versus 51.0 months, P = .92).

CONCLUSION: Among tamoxifen users, the interval from breast cancer to endometrial cancer diagnosis was significantly shorter than that in nonusers. In this cohort, a history of tamoxifen use was not associated with a worse overall or disease-specific survival.

LEVEL OF EVIDENCE: II-2

This article has been cited by other articles:

				A. Farkas and C. V. Ananth Does Tamoxifen Use Affect Prognosis in Breast Cancer Patients Who Develop Endometrial Cancer? Obstet. Gynecol., January 1, 2005; 105(1): 218 - 218. [Full Text] [PDF]

				K. A. McCaul Does Tamoxifen Use Affect Prognosis in Breast Cancer Patients Who Develop Endometrial Cancer? Obstet. Gynecol., January 1, 2005; 105(1): 217 - 218. [Full Text] [PDF]